

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Applicants: L. Alani, et al.

Serial No.:

Filed:

Title: IMPROVED PHARMACEUTICAL  
FORMULCATIONS

Case No.: 6499.US.O2

Group Art Unit: (not yet assigned)

Examiner: (not yet assigned)

Express Mail No. EL384169797US

I hereby certify that this paper  
(along with any paper referred  
to as being attached or enclosed)  
being deposited with the United States  
Postal Service as Express Mail on the  
date shown below with sufficient  
postage in an envelope addressed to  
the:

Box Patent Application  
Assistant Commissioner for Patents  
Washington, D.C. 20231, on:

Date of Deposit: May 22, 2000

*Kathleen T. Litz* 5/22/2000  
Kathleen T. Litz Date

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents  
Washington, D.C. 20231

Dear Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation in an Application" on an attached Form PTO-1449 for consideration by the Examiner.

This Information Disclosure Statement is being filed before a first Office Action on the merits in accordance with 37 C.F.R. §1.97(b). Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,  
L. Alani, et al.

*Janelle D. Strode*  
Janelle D. Strode  
Registration No. 34,738  
Attorney for Applicants

Abbott Laboratories  
Dept. 377 AP6D-2  
100 Abbott Park Road  
Abbott Park, IL 60064-6050  
Tel. No. (847) 937-4395  
Fax No. (847) 938-2623